Clinical Regulatory Services

RareMoon provides expert clinical regulatory strategy tailored to the unique challenges of rare disease drug development. Our team partners with sponsors to design and execute clinical development programs that meet regulatory expectations while addressing the complexities inherent in small patient populations and novel therapeutic modalities.

From first-in-human studies through pivotal trials and marketing applications, we guide sponsors through clinical regulatory milestones across FDA, EMA, and global health agencies. Our deep experience with gene therapies, cell therapies, and orphan drugs ensures that clinical strategies are aligned with the latest regulatory thinking on endpoints, study design, and evidentiary standards for rare diseases.